Search clinical trials for: Second-line Ibrutinib

Total 8692 results

Insel Gruppe AG, University Hospital Bern
European Organisation for Research and Treatment of Cancer - EORTC

Recruiting

Surgery for Recurrent Glioblastoma (RESURGE)

Glioblastoma

Germany, Switzerland, Austria, Greece, Italy, Portugal, Romania
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Georgetown University
Cedars-Sinai Medical Center; Thomas Jefferson University; Sinai Health System; George... and other collaborators

Withdrawn

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer (PanCAN)

Metastatic Pancreatic Cancer

United States
AstraZeneca
Quintiles, Inc.

Completed

LUMINIST: LUng Cancer Molecular Insights Non Interventional Study (LUMINIST)

NSCLC

Bulgaria, France, Italy, Mexico, Peru, Russian Federation, Spain, Turkey, United Kingdom, Sweden, Poland, Ukraine, Chile, Hungary, Israel, Netherlands, Portugal, Romania, Germany, Austria, Belgium, Canada, Australia
Central Hospital, Nancy, France

Not yet recruiting

Relevance and Efficiency of SecOnd Line Workup for Uveitis (RESOLVE)

Uveitis
Duke University

Completed

Ehealth: Second Life Impacts Diabetes Education & Self-Management (SLIDES)

Type 2 Diabetes

United States
Henan Cancer Hospital

Recruiting

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

NSCLC | Brain Metastases | Leptomeningeal Metastasis

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer
Boehringer Ingelheim

Completed

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Squamous Non-small Cell Lung Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | B-Cell Neoplasm | Small Lymphocytic Lymphoma | Asymptomatic COVID-19 Infection Laboratory-Confirmed | Symptomatic COVID-19 Infection Laboratory-Confirmed | Chronic Lymphocytic Leukemia/Small...

United States
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Zhou Fuxiang

Not yet recruiting

Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies

Stage IV Pancreatic Cancer | Hepatocellular Carcinoma , Cholangiocarcinoma

China
Université Catholique de Louvain

Completed

Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation. (DIAB-GRAFT)

Diabetes Mellitus Risk

Belgium
University of Kansas Medical Center

Completed

A Virtual Reality Intervention to Improve Weight Maintenance

Weight Loss

United States
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (4CC)

Cholangiocarcinoma

Netherlands
Shanghai Gynecologic Oncology Group
Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Shanghai Zhongshan...

Active, not recruiting

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

Fallopian Tube Carcinoma | Ovarian Epithelial Cancer Recurrent | Primary Peritoneal Carcinoma

China
Johns Hopkins University
Centers for Disease Control and Prevention

Completed

Preventing Falls Among Older Fallers to Test the Effect of LIVE-LiFE, a Home-Based, Tailored Fall Prevention Program (LIVE-LiFE)

Fall Prevention

United States
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

Healthy

Belgium
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Healthy

United States
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Chronic Lymphocytic Leukemia

Italy
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
The First Affiliated Hospital with Nanjing Medical...
Xian-Janssen Pharmaceutical Ltd.

Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
IRCCS San Raffaele

Recruiting

Real World Data on Ibrutinib Use in PCNSL Rel/Ref (ReWIPretro)

PCNSL

Italy
Memorial Sloan Kettering Cancer Center
Ohio State University; Pharmacyclics LLC.; Janssen Biotech, Inc.

Completed

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

T-cell Lymphoma | Relapsed and Refractory T-cell Lymphoma

United States
University of Cologne

Completed

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) (IRENO)

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Germany
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Medical University of Graz
Medical University of Vienna; Medical University Innsbruck; Krankenhaus Barmherzige... and other collaborators

Recruiting

Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (ADPACA)

Pancreatic Cancer | Advanced Pancreatic Carcinoma

Austria
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
University of Michigan Rogel Cancer Center

Withdrawn

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Healthy

United States
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Estonia, Hungary, Turkey, Israel, Slovakia, Bulgaria, Lithuania, Macedonia, The Former Yugoslav Republic of
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
Janssen Research & Development, LLC

Withdrawn

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell
Beijing Immunochina Medical Science & Technology...

Recruiting

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

Liver Cancer

China
Jeanette Lundin

Recruiting

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (IbruOnOff)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Sweden, Norway
Novartis Pharmaceuticals

Terminated

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Diffuse Large B-cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

United States
Johnson & Johnson Private Limited

Completed

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Ann & Robert H Lurie Children's Hospital of Chicago
Northwestern University Feinberg School of Medicine

Completed

Inhibition of Anaphylaxis by Ibrutinib

Food Allergy | Anaphylaxis Food

United States
Nanfang Hospital of Southern Medical University

Recruiting

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Colorectal Neoplasms Malignant

China
Peking University People's Hospital
Beijing Hospital

Unknown

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Leukemia, Lymphocytic, Chronic, B-Cell

Search clinical trials for: Second-line Ibrutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations